An Overview of the Development of New Vaccines for Tuberculosis
Currently, there is only one licensed vaccine against tuberculosis (TB), the Bacillus Calmette–Guérin (BCG). Despite its protective efficacy against TB in children, BCG has failed to protect adults against pulmonary TB, lacks therapeutic value, and causes complications in immunocompromised individua...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-10-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/8/4/586 |
| _version_ | 1827704810402480128 |
|---|---|
| author | E. Whitlow A. S. Mustafa S. N. M. Hanif |
| author_facet | E. Whitlow A. S. Mustafa S. N. M. Hanif |
| author_sort | E. Whitlow |
| collection | DOAJ |
| description | Currently, there is only one licensed vaccine against tuberculosis (TB), the Bacillus Calmette–Guérin (BCG). Despite its protective efficacy against TB in children, BCG has failed to protect adults against pulmonary TB, lacks therapeutic value, and causes complications in immunocompromised individuals. Furthermore, it compromises the use of antigens present in the purified protein derivate of <i>Mycobacterium tuberculosis</i> in the diagnosis of TB. Many approaches, e.g., whole-cell organisms, subunit, and recombinant vaccines are currently being explored for safer and more efficacious TB vaccines than BCG. These approaches have been successful in developing a large number of vaccine candidates included in the TB vaccine pipeline and are at different stages of clinical trials in humans. This paper discusses current vaccination strategies, provides directions for the possible routes towards the development of new TB vaccines and highlights recent findings. The efforts for improved TB vaccines may lead to new licensed vaccines capable of replacing/supplementing BCG and conferring therapeutic value in patients with active/latent TB. |
| first_indexed | 2024-03-10T15:49:25Z |
| format | Article |
| id | doaj.art-19432070fa4e46328c84716993cf632e |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-10T15:49:25Z |
| publishDate | 2020-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-19432070fa4e46328c84716993cf632e2023-11-20T16:06:54ZengMDPI AGVaccines2076-393X2020-10-018458610.3390/vaccines8040586An Overview of the Development of New Vaccines for TuberculosisE. Whitlow0A. S. Mustafa1S. N. M. Hanif2Department of Basic Sciences, Kentucky College of Osteopathic Medicine, University of Pikeville, Pikeville, KY 41501, USADepartment of Microbiology, Faculty of Medicine, Kuwait University, Safat 13110, KuwaitDepartment of Basic Sciences, Kentucky College of Osteopathic Medicine, University of Pikeville, Pikeville, KY 41501, USACurrently, there is only one licensed vaccine against tuberculosis (TB), the Bacillus Calmette–Guérin (BCG). Despite its protective efficacy against TB in children, BCG has failed to protect adults against pulmonary TB, lacks therapeutic value, and causes complications in immunocompromised individuals. Furthermore, it compromises the use of antigens present in the purified protein derivate of <i>Mycobacterium tuberculosis</i> in the diagnosis of TB. Many approaches, e.g., whole-cell organisms, subunit, and recombinant vaccines are currently being explored for safer and more efficacious TB vaccines than BCG. These approaches have been successful in developing a large number of vaccine candidates included in the TB vaccine pipeline and are at different stages of clinical trials in humans. This paper discusses current vaccination strategies, provides directions for the possible routes towards the development of new TB vaccines and highlights recent findings. The efforts for improved TB vaccines may lead to new licensed vaccines capable of replacing/supplementing BCG and conferring therapeutic value in patients with active/latent TB.https://www.mdpi.com/2076-393X/8/4/586vaccines<i>Mycobacterium tuberculosis</i>tuberculosisBCGnew vaccines |
| spellingShingle | E. Whitlow A. S. Mustafa S. N. M. Hanif An Overview of the Development of New Vaccines for Tuberculosis Vaccines vaccines <i>Mycobacterium tuberculosis</i> tuberculosis BCG new vaccines |
| title | An Overview of the Development of New Vaccines for Tuberculosis |
| title_full | An Overview of the Development of New Vaccines for Tuberculosis |
| title_fullStr | An Overview of the Development of New Vaccines for Tuberculosis |
| title_full_unstemmed | An Overview of the Development of New Vaccines for Tuberculosis |
| title_short | An Overview of the Development of New Vaccines for Tuberculosis |
| title_sort | overview of the development of new vaccines for tuberculosis |
| topic | vaccines <i>Mycobacterium tuberculosis</i> tuberculosis BCG new vaccines |
| url | https://www.mdpi.com/2076-393X/8/4/586 |
| work_keys_str_mv | AT ewhitlow anoverviewofthedevelopmentofnewvaccinesfortuberculosis AT asmustafa anoverviewofthedevelopmentofnewvaccinesfortuberculosis AT snmhanif anoverviewofthedevelopmentofnewvaccinesfortuberculosis AT ewhitlow overviewofthedevelopmentofnewvaccinesfortuberculosis AT asmustafa overviewofthedevelopmentofnewvaccinesfortuberculosis AT snmhanif overviewofthedevelopmentofnewvaccinesfortuberculosis |